ArticleFrontiers in oncology2026
Prognostic nutritional index in evaluating the prognosis of ICIs in patients with advanced esophageal squamous carcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the association between the Prognostic Nutritional Index (PNI) and the prognosis of advanced esophageal squamous cell carcinoma (ESCC) patients treated with immune checkpoint inhibitors (ICIs). Methods: We retrospectively analyzed the clinical data of 157 advanced ESCC patients who received ICIs therapy at Hengshui People's Hospital. The PNI was calculated based on serum albumin levels and lymphocyte counts. The predictive value of PNI for disease progression in advanced ESCC patients was evaluated using receiver operating characteristic (ROC) curve analysis. Results: Among 157 patients with advanced ESCC, the complete response (CR) rate was 0.64% (1/157), partial response (PR) rate was 47.13% (74/157), stable disease (SD) rate was 38.22% (60/157), and progressive disease (PD) rate was 14.01% (22/157). The median progression-free survival (PFS) was 14.2 months. During the follow-up period, 80 patients died, leading to a mortality rate of 50.96%. The CR+PR group showed significantly higher albumin levels, lymphocyte counts, and PNI compared to the PD group ( Conclusion: PNI is associated with the efficacy of ICI therapy and prognosis in patients with advanced ESCC, suggesting its potential as a promising prognostic stratification marker. However, the clinical utility of PNI as an independent biomarker requires further validation through prospective, multicenter studies with larger sample sizes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.